Literature DB >> 7321526

Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion.

C S Raine, L Scheinberg, J M Waltz.   

Abstract

Oligodendrocytes have been studied ultrastructurally in relationship to areas of active demyelination in multiple sclerosis. The tissue came from a central nervous system plaque sampled at biopsy during a neurosurgical procedure to correct severe intention tremor in a case of chronic progressive multiple sclerosis. Cells interpreted as oligodendrocytes were abundant within the demyelinated zone, were easily identifiable, and sometimes occurred as nests of cells suggestive of proliferation. Oligodendrocytes were also common within areas of active demyelination where numerous macrophages displayed active phagocytosis of myelin. These oligodendrocytes were paler and perhaps represented residual, surviving cells. In the relatively normal white matter adjacent to the plaque, increased numbers of oligodendrocytes occurred in association with remyelination. In the demyelinated zone, the astrocyte:macrophage:oligodendrocyte ratio was 1:2.25:4.5; within the region of ongoing demyelination, 1:4:4; and in the adjacent white matter, 1:0.1:2.1. On the basis of an apparent proliferation and survival of oligodendrocytes, the findings support the notions that there is no selective depletion of oligodendrocytes either during or shortly following central nervous system demyelination in multiple sclerosis, and that the myelin sheath is the primary target.

Entities:  

Mesh:

Year:  1981        PMID: 7321526

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  47 in total

1.  Chronic remitting experimental allergic encephalomyelitis in Lewis rats as a model of multiple sclerosis.

Authors:  E Zapryanova; D Deleva; M Bakalska; N Filchev
Journal:  Neurosci Behav Physiol       Date:  1999 Jan-Feb

2.  Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody.

Authors:  D R Wren; M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 3.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

Review 4.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

5.  Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1.

Authors:  Kakuri M Omari; Sarah E Lutz; Laura Santambrogio; Sergio A Lira; Cedric S Raine
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

Review 6.  Do oligodendrocytes divide?

Authors:  W T Norton
Journal:  Neurochem Res       Date:  1996-04       Impact factor: 3.996

7.  Induction of myelination in the central nervous system by electrical activity.

Authors:  C Demerens; B Stankoff; M Logak; P Anglade; B Allinquant; F Couraud; B Zalc; C Lubetzki
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

8.  The chemokine growth-regulated oncogene-alpha promotes spinal cord oligodendrocyte precursor proliferation.

Authors:  S Robinson; M Tani; R M Strieter; R M Ransohoff; R H Miller
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

9.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

10.  Myelin basic protein does not have a mitogenic effect on adult oligodendrocytes.

Authors:  G R Moore; S U Kim; E Chang; M Kim
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.